Lansoprazole

also known as prevacid · Lansoprazole (generic name) · Takepron · Takepron OD · A-65006 · AD-2121 · AG-1749 · Agopton · +22 more

Other / unclassified

Developed for: gastroesophageal reflux disease · Helicobacter pylori infectious disease · dyspepsia · gastric ulcer · duodenal ulcer · esophagitis · asthma · peptic ulcer disease
+31 more
· type 1 diabetes mellitus · upper respiratory tract disorder · Barrett esophagus · gastritis · otitis media with effusion · achalasia · cardiac rhythm disease · chronic lymphocytic leukemia/small lymphocytic lymphoma · esophageal varices with bleeding · gastric diffuse large B-cell lymphoma · hearing loss disorder · idiopathic pulmonary fibrosis · laryngeal disorder · lung disorder · multiple endocrine neoplasia · nasal cavity polyp · obstructive sleep apnea syndrome · peptic esophagitis · pseudomyxoma peritonei · pseudoxanthoma elasticum (inherited or acquired) · rhinitis · Zollinger-Ellison syndrome · active peptic ulcer disease · breast cancer · gastric cancer · hemorrhagic disease · lymphoma · membranous glomerulonephritis · nephrotic syndrome · proton-pump inhibitor-responsive esophageal eosinophilia · voice disorders
Investigated by: Takeda · National Taiwan University Hospital · AstraZeneca · Novartis · TAP Pharmaceutical Products Inc. · Janssen Research & Development, LLC
+96 more
· Teva Pharmaceuticals USA · Beijing Xuze Medical Technology Co., LTD. · Emory University · First Affiliated Hospital of Zhejiang University · Mackay Memorial Hospital · Mahidol University · National Cheng-Kung University Hospital · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Nemours Children's Clinic · Seoul National University Hospital · Stanford University · Addpharma Inc. · American Institute for Voice and Ear Research · American Lung Association Asthma Clinical Research Centers · American University of Beirut Medical Center · Arkansas Children's Hospital Research Institute · Augusta University · Bill and Melinda Gates Foundation · Boston Children's Hospital · Chang Gung Memorial Hospital · Changhua Christian Hospital · Charles Mel Wilcox, MD · Children's Mercy Hospital Kansas City · China Medical University Hospital · Cinclus Pharma Holding AB · Dallas VA Medical Center · Deva Holding A.S. · Doris Duke Charitable Foundation · Dow University of Health Sciences · E-DA Hospital · Fondo Nacional de Desarrollo Científico y Tecnológico, Chile · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · HK inno.N Corporation · Hamamatsu University · Hamilton Health Sciences Corporation · Head and Neck Surgery Associates · Hodge, Kenneth M., M.D. · Hualien Tzu Chi General Hospital · Il-Yang Pharm. Co., Ltd. · Inje University · James Cook University Hospital · Jason Lang, M.D., M.P.H. · Jiangsu Carephar Pharmaceutical Co., Ltd. · Jiangsu Sinorda Biomedicine Co., Ltd · Johns Hopkins University · Jordan Collaborating Cardiology Group · Juvenile Diabetes Research Foundation · Kaohsiung Medical University · King Saud University · King's College Hospital NHS Trust · LCMC Health · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Lotung Poh-Ai Hospital · McGill University Health Centre/Research Institute of the McGill University Health Centre · McMaster University · Medela AG · Mercy Medical Center · MetroHealth Medical Center · Miguel O'Ryan Gallardo · National Cancer Center, Korea · National Health Research Institutes, Taiwan · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Dental and Craniofacial Research (NIDCR) · Neutec Ar-Ge San ve Tic A.Ş · Norfolk and Norwich University Hospitals NHS Foundation Trust · Norwich Clinical Trials Unit · Nîmes University Hospital · Osaka University · Parexel · Perle Bioscience, Inc. · Puma Biotechnology, Inc. · Quotient Sciences · Ramathibodi Hospital · SWOG Cancer Research Network · all 102 on the full record

Regulatory milestones approvals, filings & regulatory actions · 12 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (11)	US (FDA)	PREVACID	—	1996-04-08 – 2008-10-28	fda.gov ↗
Approved	US (FDA)	PREVACID	—	1995-05-10	fda.gov ↗

Trials 109 · started per year

today

US approved 1995

1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04400136	Jul 2020 → Jul 2021	Barrett esophagus, gastroesophageal reflux disease	University of Roma La Sapienza	Unknown	No outcome recorded
Phase 121 trials
Phase 1	NCT06025773	Sep 2023 → Apr 2024	gastroesophageal reflux disease	Addpharma Inc.	Completed	No outcome recorded
Phase 1	NCT05050188	Jun → Sep 2021	esophagitis	Jiangsu Carephar Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04453189	Jul → Sep 2020	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT03710434	Nov 2018 → Apr 2019	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03488186	Jul → Oct 2018	—	First Affiliated Hospital of Zhejiang University	Completed	No outcome recorded
Phase 1	NCT03488173	Apr → Jul 2018	—	First Affiliated Hospital of Zhejiang University	Completed	No outcome recorded
Phase 1	NCT03468777	Mar → Jul 2018	—	Janssen Research & Development, LLC	Terminated	No outcome recorded
Phase 1	NCT03059303	Feb → Apr 2017	—	Janssen Research & Development, LLC	Terminated	No outcome recorded
Phase 1	NCT02334501	Aug → Oct 2014	—	Puma Biotechnology, Inc.	Completed	No outcome recorded
Phase 1	NCT01820104	Mar → May 2013	—	Xijing Hospital	Completed	No outcome recorded
Phase 1	NCT02022280	Mar 2013 → May 2014	—	Stanford University	Completed	No outcome recorded
Phase 1	NCT01147588	May 2010 → May 2011	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00942175	Dec 2009 → Jun 2010	—	Takeda	Completed	No outcome recorded
Phase 1	NCT00952913	Aug → Oct 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 1	NCT00458614	Jun 2006 → Apr 2007	cystic fibrosis	Arkansas Children's Hospital Research Institute	Completed	No outcome recorded
Phase 1	NCT00864396	Jul 2005 → May 2008	upper respiratory tract disorder	University of California, Davis	Completed	No outcome recorded
Phase 1	NCT00174928	May → Aug 2005	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 1	NCT00220818	Jan → Jul 2005	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 1	NCT01045967	May → Jun 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT01046253	Jan 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT01046084	Aug → Sep 2003	—	Teva Pharmaceuticals USA	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT01946971	Sep 2013 → Jul 2014	gastroesophageal reflux disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 210 trials
Phase 2	NCT07076914	Oct 2025 → Jan 2028 expected	non-small cell lung carcinoma, small cell lung carcinoma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Not yet recruiting	No outcome recorded
Phase 2	NCT05055128	Aug 2021 → Sep 2022	esophagitis	Cinclus Pharma Holding AB	Completed	No outcome recorded
Phase 2	NCT04531475	Jan → Oct 2020	peptic esophagitis	Jiangsu Sinorda Biomedicine Co., Ltd	Completed	No outcome recorded
Phase 2	NCT02387203	Jan 2015 → Dec 2024 overdue	pseudomyxoma peritonei	Mercy Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT02388581	Dec 2014 → Dec 2017	gastric diffuse large B-cell lymphoma	National Health Research Institutes, Taiwan	Unknown	No outcome recorded
Phase 2	NCT01778101	Jan → May 2013	gastroesophageal reflux disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 2	NCT01279252	Jul 2011 → Jan 2015	chronic lymphocytic leukemia/small lymphocytic lymphoma	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 2	NCT01155284	Aug 2010 → May 2014	type 1 diabetes mellitus	Sanford Health	Completed	No outcome recorded
Phase 2	NCT01037452	Dec 2009 → Jan 2010	dyspepsia	Novartis	Completed	No outcome recorded
Phase 2	NCT00837759	Feb 2009 → Mar 2011	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT07337655	Oct 2026 → Sep 2030 expected	—	Stanford University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT00789061	Aug 2006 → Mar 2008	hearing loss disorder	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 323 trials
Phase 3	NCT06284876	Jul 2024 → Aug 2026 overdue	peptic ulcer disease	Il-Yang Pharm. Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT04965298	Jun 2021 → Feb 2026 overdue	idiopathic pulmonary fibrosis	Norfolk and Norwich University Hospitals NHS Foundation Trust	Recruiting	No outcome recorded
Phase 3	NCT03015610	Oct 2017 → Jan 2024	asthma, gastroesophageal reflux disease	Jason Lang, M.D., M.P.H.	Completed	No outcome recorded
Phase 3	NCT03317223	Oct 2017 → Jan 2019	Helicobacter pylori infectious disease	HK inno.N Corporation	Completed	No outcome recorded
Phase 3	NCT03050307	Apr 2017 → Feb 2020	gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT03050359	Apr 2017 → Mar 2019	duodenal ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT02873702	Dec 2016 → Oct 2017	esophagitis	Takeda	Terminated	No outcome recorded
Phase 3	NCT02557932	Sep 2015 → Dec 2018	Helicobacter pylori infectious disease, hereditary gastric cancer	National Cancer Center, Korea	Completed	No outcome recorded
Phase 3	NCT02388737	Apr 2015 → Dec 2018	esophagitis	Takeda	Completed	No outcome recorded
Phase 3	NCT01762657	Sep 2014 → Sep 2015	type 1 diabetes mellitus	Perle Bioscience, Inc.	Withdrawn	No outcome recorded
Phase 3	NCT01505127	Jan 2012 → Jun 2013	Helicobacter pylori infectious disease	Takeda	Completed	No outcome recorded
Phase 3	NCT01481844	Nov 2011 → Dec 2014	—	Soroka University Medical Center	Completed	No outcome recorded
Phase 3	NCT01182597	Aug 2010 → Aug 2013	peptic ulcer disease	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 3	NCT01131026	Jun 2010 → Aug 2011	Helicobacter pylori infectious disease	Deva Holding A.S.	Completed	No outcome recorded
Phase 3	NCT01061437	Jun 2009 → Jul 2011	Helicobacter pylori infectious disease	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 3	NCT00762359	May 2007 → Nov 2008	duodenal ulcer, gastric ulcer	Takeda	Terminated	No outcome recorded
Phase 3	NCT00787254	Apr 2007 → May 2009	duodenal ulcer, gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT00701259	Jan → Aug 2007	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00389948	Jun 2006 → Jan 2007	dyspepsia	Novartis	Completed	No outcome recorded
Phase 3	NCT00324974	Jun 2006 → May 2007	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00390390	Jun 2006 → Jan 2007	dyspepsia	Novartis	Completed	No outcome recorded
Phase 3	NCT00175032	Jul 2003 → Jul 2004	osteoarthritis, peptic ulcer disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00149084	Apr 2003 → ?	Helicobacter pylori infectious disease, duodenal ulcer, gastric ulcer, gastritis	Hamamatsu University	Unknown	No outcome recorded

Phase 440 trials
Phase 4	NCT07611162	May 2026 → May 2030 expected	gastroesophageal reflux disease	University of Mons	Not yet recruiting	No outcome recorded
Phase 4	NCT07344506	May 2025 → May 2026 overdue	Helicobacter pylori infectious disease	Dow University of Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT05624229	Oct 2023 → Dec 2025 overdue	esophageal varices with bleeding	West China Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT05711810	Jan 2023	Orthocoronavirinae infectious disease, myocarditis	Yang I. Pachankis	Completed	No outcome recorded
Phase 4	NCT04713670	Mar 2021 → Dec 2025 overdue	Helicobacter pylori infectious disease	National Taiwan University Hospital	Recruiting	No outcome recorded
Phase 4	NCT04660461	Feb 2020 → Jun 2021	pseudoxanthoma elasticum (inherited or acquired)	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	Unknown	No outcome recorded
Phase 4	NCT04248335	Jul 2018 → Dec 2024	gastroesophageal reflux disease, metabolic dysfunction-associated steatotic liver disease	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 4	NCT03524833	May 2018 → Jan 2019	Helicobacter pylori infectious disease	Mackay Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT03273634	May 2017 → May 2018	cardiac rhythm disease	Jordan Collaborating Cardiology Group	Completed	No outcome recorded
Phase 4	NCT03130452	Dec 2016 → Jan 2019	Helicobacter pylori infectious disease	Inje University	Completed	No outcome recorded
Phase 4	NCT02794844	Jul 2016 → Jan 2017	gastroesophageal reflux disease	Nemours Children's Clinic	Completed	No outcome recorded
Phase 4	NCT02759393	Oct 2015 → Jul 2017	gastroesophageal reflux disease	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT02278081	Jan 2015 → Jan 2016	gastroesophageal reflux disease, rhinitis	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
Phase 4	NCT02958046	Jan 2014 → May 2015	gastroesophageal reflux disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT01906879	Jun 2013 → Dec 2017	Helicobacter pylori infectious disease	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT01888237	May 2013 → Aug 2014	dyspepsia, gastritis	Mahidol University	Completed	No outcome recorded
Phase 4	NCT01607918	Feb 2012 → Dec 2013	—	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT01537055	Feb 2012 → Dec 2015	—	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT02703896	Jan 2012	lung disorder	King Saud University	Completed	No outcome recorded
Phase 4	NCT01512953	Jan 2011 → Aug 2012	coronary artery disorder	Università degli Studi di Ferrara	Unknown	No outcome recorded
Phase 4	NCT01082029	Mar 2010 → Jun 2014	otitis media with effusion	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT01042184	Dec 2009 → Feb 2012	Helicobacter pylori infectious disease	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT01040455	Dec 2009 → Dec 2013	dyspepsia	National Taiwan University Hospital	Terminated	No outcome recorded
Phase 4	NCT00472186	Jun 2008 → Feb 2011	—	Boston Children's Hospital	Terminated	No outcome recorded
Phase 4	NCT00663897	May 2008 → Jul 2009	dyspepsia	Lotung Poh-Ai Hospital	Completed	No outcome recorded
Phase 4	NCT01404832	Oct 2007 → May 2010	eosinophilic esophagitis, gastroesophageal reflux disease	Dallas VA Medical Center	Terminated	No outcome recorded
Phase 4	NCT00444145	Mar 2007 → Mar 2009	gastroesophageal reflux disease, laryngeal disorder	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT00442013	Mar 2007 → Apr 2011	asthma	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00410592	Oct 2006 → May 2007	gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00369265	Aug 2006 → Nov 2009	upper respiratory tract disorder	American Institute for Voice and Ear Research	Terminated	No outcome recorded
Phase 4	NCT00237068	Mar 2006 → Dec 2009	asthma	Emory University	Unknown	No outcome recorded
Phase 4	NCT00467571	Mar 2006 → Sep 2008	Helicobacter pylori infectious disease, autoimmune thrombocytopenic purpura	Mahidol University	Completed	No outcome recorded
Phase 4	NCT00352261	Jan 2006 → Apr 2007	Barrett esophagus	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00239551	Oct 2005 → Oct 2006	gastric ulcer	Emory University	Completed	No outcome recorded
Phase 4	NCT00230516	Sep 2005 → Feb 2006	—	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00220909	Sep 2005 → Jan 2006	—	Temple University	Terminated	No outcome recorded
Phase 4	NCT00625274	Jun → Nov 2004	dyspepsia, gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00204373	Mar 2003 → Dec 2010	Zollinger-Ellison syndrome, multiple endocrine neoplasia	Charles Mel Wilcox, MD	Completed	No outcome recorded
Phase 4	NCT01135368	Jun 2002 → Sep 2008	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 4	NCT00299845	—	gastroesophageal reflux disease	Osaka University	Withdrawn	No outcome recorded

Phase not applicable11 trials
—	NCT06778824	Apr 2024 → Dec 2025 overdue	gastroesophageal reflux disease	Hualien Tzu Chi General Hospital	Recruiting	No outcome recorded
—	NCT05899842	Jun 2023 → Feb 2028 expected	achalasia	Nîmes University Hospital	Recruiting	No outcome recorded
—	NCT05926804	Aug 2022 → Oct 2026 expected	Helicobacter pylori infectious disease	Miguel O'Ryan Gallardo	Recruiting	No outcome recorded
—	NCT03859102	Dec 2018 → Oct 2019	aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2	James Cook University Hospital	Unknown	No outcome recorded
—	NCT02788591	Aug 2015 → Jun 2021	gastroesophageal reflux disease	LCMC Health	Terminated	No outcome recorded
—	NCT01568944	Mar 2012 → Sep 2014	chronic periodontitis	Augusta University	Completed	No outcome recorded
—	NCT01139645	Oct 2009 → Jul 2010	calcium metabolic disease	American University of Beirut Medical Center	Completed	No outcome recorded
—	NCT00546117	Oct 2007 → Dec 2009	otitis media with effusion	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00211614	Jul → Sep 2006	gastroesophageal reflux disease, obstructive sleep apnea syndrome	MetroHealth Medical Center	Withdrawn	No outcome recorded
—	NCT00274339	Dec 2005 → Jun 2008	upper respiratory tract disorder	Hodge, Kenneth M., M.D.	Unknown	No outcome recorded
—	NCT00215787	Sep 2005 → Sep 2008	gastroesophageal reflux disease, nasal cavity polyp	Head and Neck Surgery Associates	Completed	No outcome recorded

Also used as a comparator or background therapy in 111 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT04729101 Comparator	Jan → Jun 2021	—	Phathom Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03487562 Background	Apr 2018 → Jan 2019	—	Daewoong Pharmaceutical Co. LTD.	Completed	No outcome recorded
Phase 1	NCT03120273 Comparator	May → Aug 2017	—	First Affiliated Hospital of Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT02892409 Comparator	Sep 2016 → Apr 2017	Helicobacter pylori infectious disease	Takeda	Completed	No outcome recorded
Phase 1	NCT02625259 Background	Jan → May 2016	neoplasm	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT01681186 Background	Sep → Dec 2012	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT03654781 Background	Apr 2008 → Jul 2011	Helicobacter pylori infectious disease	Ondokuz Mayıs University	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT01129713 Comparator	May 2010 → May 2015	dyspepsia, gastroesophageal reflux disease	Effexus Pharmaceutical	Unknown	No outcome recorded
Phase 1/2	NCT00685295 Comparator	Aug 2008 → Feb 2009	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 212 trials
Phase 2	NCT07708545 Comparator	Jul → Dec 2026 expected	peptic ulcer disease	Indonesia University	Not yet recruiting	No outcome recorded
Phase 2	NCT04188119 Background	Dec 2023 → Sep 2024	breast cancer	The Christie NHS Foundation Trust	Withdrawn	No outcome recorded
Phase 2	NCT05933031 Comparator	Feb 2023 → Dec 2024	Helicobacter pylori infectious disease	HK inno.N Corporation	Unknown	No outcome recorded
Phase 2	NCT03794596 Background	Sep 2019 → Feb 2021	breast cancer	The Christie NHS Foundation Trust	Withdrawn	No outcome recorded
Phase 2	NCT03192059 Background	Jul 2017 → Jun 2021	cervical cancer, endometrial cancer	University Hospital, Ghent	Completed	No outcome recorded
Phase 2	NCT02637557 Background	Mar 2016 → Apr 2017	gastroesophageal reflux disease	Ironwood Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02288078 Comparator	Oct 2014 → Sep 2015	rectal cancer	Clinical Research Support Center Kyush	Unknown	No outcome recorded
Phase 2	NCT02128490 Background	May 2014 → Sep 2015	gout	Takeda	Completed	No outcome recorded
Phase 2	NCT00978016 Background	Sep 2009 → Dec 2010	gastroesophageal reflux disease	XenoPort, Inc.	Completed	No outcome recorded
Phase 2	NCT00638456 Comparator	Feb 2008 → Sep 2009	eosinophilic esophagitis	Ranjan Dohil	Completed	No outcome recorded
Phase 2	NCT00471094 Comparator	May → Oct 2007	esophagitis	Takeda	Completed	No outcome recorded
Phase 2	NCT00175045 Comparator	Jun → Oct 2003	esophagitis, gastroesophageal reflux disease	Takeda	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT05861687 Comparator	Aug → Dec 2021	Helicobacter pylori infectious disease	Finni Kollins	Completed	No outcome recorded
Phase 2/3	NCT00361972 Comparator	Aug 2006 → Apr 2009	asthma, gastroesophageal reflux disease	University of Utah	Terminated	No outcome recorded
Phase 336 trials
Phase 3	NCT07313774 Comparator	Mar 2026 → Sep 2028	gastroesophageal reflux disease	Cinclus Pharma Holding AB	Withdrawn	No outcome recorded
Phase 3	NCT07037875 Comparator	Sep 2025 → Aug 2026 overdue	gastroesophageal reflux disease	Cinclus Pharma Holding AB	Recruiting	No outcome recorded
Phase 3	NCT06964334 Comparator	Jun 2025 → Jun 2026 overdue	Helicobacter pylori infectious disease	Assiut University	Not yet recruiting	No outcome recorded
Phase 3	NCT05448001 Comparator	Sep 2022 → Jul 2024	gastric ulcer	Onconic Therapeutics Inc.	Completed	No outcome recorded
Phase 3	NCT05010954 Comparator	Oct 2021 → Sep 2022	duodenal ulcer	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT07079540 Comparator	Jun 2021 → Jul 2022	peptic esophagitis	Jiangsu Sinorda Biomedicine Co., Ltd	Completed	No outcome recorded
Phase 3	NCT04874935 Comparator	Jun 2021 → Nov 2022	breast cancer	Tanta University	Completed	No outcome recorded
Phase 3	NCT05417997 Background	May → Dec 2021	COVID-19, bacterial pneumonia, influenza	RAAS Nutritionals, LLC	Completed	No outcome recorded
Phase 3	NCT04840550 Comparator	May 2021 → Jun 2024	peptic ulcer disease	HK inno.N Corporation	Unknown	No outcome recorded
Phase 3	NCT04341428 Comparator	Jul 2020 → Aug 2021	esophagitis	Daewoong Pharmaceutical Co. LTD.	Unknown	No outcome recorded
Phase 3	NCT04325633 Background	Apr → Dec 2020	COVID-19	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT04167670 Comparator	Dec 2019 → Mar 2021	Helicobacter pylori infectious disease	Phathom Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 3	NCT04124926 Comparator	Oct 2019 → Jul 2021	esophagitis	Phathom Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 3	NCT04022096 Comparator	Jun 2019 → Jun 2021	esophagitis	HK inno.N Corporation	Completed	No outcome recorded
Phase 3	NCT03647072 Comparator	Aug 2018 → Oct 2027 expected	lymphoma	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT03498456 Comparator	Jun 2018 → Dec 2019	Helicobacter pylori infectious disease	HK inno.N Corporation	Completed	No outcome recorded
Phase 3	NCT02761512 Comparator	May 2016 → Jul 2018	gastric ulcer	HK inno.N Corporation	Completed	No outcome recorded
Phase 3	NCT02388724 Comparator	Mar 2015 → Jul 2017	esophagitis	Takeda	Completed	No outcome recorded
Phase 3	NCT02112214 Comparator	Jun 2014 → Dec 2029 expected	Helicobacter pylori infectious disease, gastric cancer	National Cancer Center, Korea	Active not recruiting	No outcome recorded
Phase 3	NCT02139046 Background	Apr 2014 → Nov 2015	gout	Takeda	Completed	No outcome recorded
Phase 3	NCT02726269 Comparator	Jun 2012 → Mar 2014	Helicobacter pylori infectious disease	Asofarma de México S.A de C.V.	Completed	No outcome recorded
Phase 3	NCT01456247 Comparator	Mar 2012 → Oct 2013	duodenal ulcer, gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01452711 Comparator	Nov 2011 → Dec 2012	gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01459367 Comparator	Oct 2011 → Mar 2013	esophagitis	Takeda	Completed	No outcome recorded
Phase 3	NCT01452750 Comparator	Oct 2011 → Jun 2013	duodenal ulcer, gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01452724 Comparator	Oct 2011 → Feb 2013	duodenal ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01452763 Comparator	Oct 2011 → Apr 2013	duodenal ulcer, gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01456260 Comparator	Sep 2011 → Dec 2013	duodenal ulcer, gastric ulcer	Takeda	Completed	No outcome recorded
Phase 3	NCT01509261 Comparator	Jul 2010 → Jun 2011	esophagitis, gastroesophageal reflux disease	Il-Yang Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01005719 Comparator	Sep 2009 → Jan 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT02150447 Comparator	Jun 2009 → Apr 2015	gastric cancer, hemorrhagic disease	National Cancer Center, Korea	Terminated	No outcome recorded
Phase 3	NCT00335283 Comparator	Aug 2006 → Dec 2008	laryngeal disorder	Vanderbilt University	Completed	No outcome recorded
Phase 3	NCT00251719 Comparator	Dec 2005 → Jan 2007	gastroesophageal reflux disease, peptic esophagitis	Takeda	Completed	No outcome recorded
Phase 3	NCT00251693 Comparator	Dec 2005 → Jan 2007	gastroesophageal reflux disease, peptic esophagitis	Takeda	Completed	No outcome recorded
Phase 3	NCT01678027 Comparator	Nov 2004 → Dec 2018 overdue	Helicobacter pylori infectious disease, gastric cancer	National Cancer Center, Korea	Active not recruiting	No outcome recorded
Phase 3	NCT01452698 Comparator	? → Aug 2012	esophagitis	Takeda	Completed	No outcome recorded

Phase 439 trials
Phase 4	NCT07533266 Comparator	Apr 2026 → Dec 2027 expected	—	Daewoong Pharmaceutical Co. LTD.	Not yet recruiting	No outcome recorded
Phase 4	NCT05761015 Background	Dec 2023 → Apr 2028 expected	chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee	University Hospital, Clermont-Ferrand	Recruiting	No outcome recorded
Phase 4	NCT06156085 Comparator	Nov 2023 → Nov 2024	Helicobacter pylori infectious disease	Fu Jen Catholic University Hospital	Completed	No outcome recorded
Phase 4	NCT05946135 Comparator	Nov 2023 → Sep 2025	—	Yonsei University	Completed	No outcome recorded
Phase 4	NCT05820048 Comparator	May 2023 → Apr 2024	coronary artery disorder	Daejeon St. Mary's hospital	Unknown	No outcome recorded
Phase 4	NCT05259007 Background	Feb → Mar 2022	Helicobacter pylori infectious disease	Fatma Zehra Arvas	Unknown	No outcome recorded
Phase 4	NCT05371249 Comparator	Dec 2021 → Dec 2023	Helicobacter pylori infectious disease	Fu Jen Catholic University Hospital	Completed	No outcome recorded
Phase 4	NCT05184491 Background	Oct 2021 → Feb 2022	Helicobacter pylori infectious disease	National Liver Institute, Egypt	Unknown	No outcome recorded
Phase 4	NCT05267743 Comparator	Feb 2021 → May 2022	gastroesophageal reflux disease	HK inno.N Corporation	Completed	No outcome recorded
Phase 4	NCT04660123 Background	Dec 2020 → Dec 2021	Helicobacter pylori infectious disease, gastric cancer	Xijing Hospital of Digestive Diseases	Completed	No outcome recorded
Phase 4	NCT04101708 Comparator	Sep 2019 → Sep 2021	Helicobacter pylori infectious disease	Shandong University	Unknown	No outcome recorded
Phase 4	NCT03094416 Background	Jul 2018 → Jun 2020	postsurgical hypothyroidism	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 4	NCT03571230 Background	Jul 2018 → Dec 2019	Helicobacter pylori infectious disease	Shandong University	Unknown	No outcome recorded
Phase 4	NCT03355170 Comparator	Mar → Dec 2018	gastroesophageal reflux disease, heart disorder	Neutec Ar-Ge San ve Tic A.Ş	Withdrawn	No outcome recorded
Phase 4	NCT03124420 Comparator	Apr → Dec 2017	Helicobacter pylori infectious disease	Mackay Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT02530879 Comparator	May 2016 → Aug 2017	upper respiratory tract disorder	Temple University	Withdrawn	No outcome recorded
Phase 4	NCT02679508 Comparator	Mar 2016 → Mar 2022	esophagitis	Takeda	Completed	No outcome recorded
Phase 4	NCT02633930 Background	Dec 2015 → Jun 2016	dyspepsia, gastritis, peptic ulcer disease	Xijing Hospital of Digestive Diseases	Completed	No outcome recorded
Phase 4	NCT02175901 Background	Jul 2014 → Jan 2015	dyspepsia, peptic ulcer disease	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02175927 Background	Jul 2014 → Oct 2015	—	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02755753 Background	Jan 2014 → Jan 2016	gastroesophageal reflux disease	YongChan Lee	Completed	No outcome recorded
Phase 4	NCT01668927 Background	Jul → Sep 2012	dyspepsia, peptic ulcer disease	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01667718 Background	May → Oct 2012	dyspepsia, peptic ulcer disease	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01506986 Comparator	Mar 2012 → Oct 2017	Helicobacter pylori infectious disease, peptic ulcer disease	University of Nottingham	Completed	No outcome recorded
Phase 4	NCT01418300 Comparator	Aug 2010 → Aug 2011	Helicobacter pylori infectious disease	Jun-Won Chung	Completed	No outcome recorded
Phase 4	NCT01180179 Comparator	Jun 2010 → May 2019	peptic ulcer disease	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT01123031 Comparator	Apr 2010 → Mar 2012	active peptic ulcer disease	Changhua Christian Hospital	Withdrawn	No outcome recorded
Phase 4	NCT00708149 Comparator	Jun 2009 → Feb 2012	respiratory failure	Far Eastern Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00903448 Comparator	Apr → Jun 2009	—	Procter and Gamble	Completed	No outcome recorded
Phase 4	NCT00825630 Comparator	Nov 2008 → Nov 2009	Helicobacter pylori infectious disease	Meridian Bioscience, Inc.	Completed	No outcome recorded
Phase 4	NCT00926809 Comparator	Sep 2008 → Sep 2010	ulcer disease	Korean College of Helicobacter and Upper Gastrointestinal Research	Unknown	No outcome recorded
Phase 4	NCT00729339 Comparator	Jun 2008 → Apr 2009	gastroesophageal reflux disease	Lotung Poh-Ai Hospital	Completed	No outcome recorded
Phase 4	NCT00637416 Comparator	Mar 2008 → Jul 2009	voice disorders	University of Kansas Medical Center	Terminated	No outcome recorded
Phase 4	NCT00816140 Background	Jun 2007 → Jul 2009	Helicobacter pylori infectious disease	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT01008696 Comparator	May 2007 → Aug 2008	esophagitis	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00641602 Comparator	Dec 2002 → Aug 2003	esophagitis	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00644735 Comparator	Dec 2002 → Jan 2004	esophagitis	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00637845 Comparator	Jun 2002 → Feb 2003	dyspepsia, gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT02251184 Background	Oct → Nov 2000	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase not applicable13 trials
—	NCT06894992 Comparator	May → Dec 2025 overdue	active peptic ulcer disease	Mario Steffanus	Recruiting	No outcome recorded
—	NCT06945237 Background	Apr → Aug 2025	gastroesophageal reflux disease	RenJi Hospital	Completed	No outcome recorded
—	NCT06931223 Background	Apr → Sep 2025 overdue	dyspepsia	RenJi Hospital	Not yet recruiting	No outcome recorded
—	NCT07479056 Comparator	Oct 2024 → Apr 2028 expected	acute coronary syndrome, coronary artery disorder	SUK MIN SEO	Recruiting	No outcome recorded
—	NCT04674774 Comparator	Mar 2021 → Feb 2022	Helicobacter pylori infectious disease	Incheon St.Mary's Hospital	Unknown	No outcome recorded
—	NCT03418337 Comparator	Aug 2017 → Jul 2018	proton-pump inhibitor-responsive esophageal eosinophilia	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
—	NCT01643785 Background	Jun 2012 → Jun 2013	Helicobacter pylori infectious disease	Chuncheon Sacred Heart Hospital	Terminated	No outcome recorded
—	NCT01175200 Comparator	Sep 2010 → Jul 2012	platelet aggregation, spontaneous	Ascopharm Groupe Novasco	Completed	No outcome recorded
—	NCT01216267 Comparator	Jun 2010 → Jan 2012	neuroendocrine carcinoma	University of Western Ontario, Canada	Completed	No outcome recorded
—	NCT01039558 Comparator	Dec 2009 → Mar 2011	gastroesophageal reflux disease	Seoul National University Hospital	Completed	No outcome recorded
—	NCT00854776 Comparator	Jan 2009 → Dec 2010	peptic ulcer disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
—	NCT00983034 Comparator	Mar 2006 → Dec 2008	membranous glomerulonephritis, nephrotic syndrome	Istanbul University	Completed	No outcome recorded
—	NCT00573924 Comparator	Feb 2006 → Dec 2007	peptic ulcer disease	University of Southern California	Completed	No outcome recorded

Press releases naming this drug 9 releases

Date	Issuer	Release
2014-06-12	Takeda	Takelda ® Combination Tablets, the Fixed-Dose Combination of Lansoprazole and Low-Dose Aspirin, is Now Available in Japan takeda.com ↗
2014-03-24	Takeda	Takeda Announces the New Drug Application Approval of TAKELDA ® Combination Tablets, the Fixed Dose Combination of TAKEPRON ® and Low-Dose Aspirin, in Japan takeda.com ↗
2010-10-18	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Generic Prevacid® SoluTab in the United States tevapharm.com ↗
2010-01-22	Teva Branded Pharmaceutical Products R&D, Inc.	Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab tevapharm.com ↗
2009-11-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Final Approval For Generic Prevacid® Delayed-Release Capsules tevapharm.com ↗
2009-11-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Favorable Court Decision Regarding Generic Prevacid® Solutab tevapharm.com ↗
2008-11-09	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update on Generic Prevacid® Litigation tevapharm.com ↗
2008-03-31	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update On Generic Prevacid® Litigation tevapharm.com ↗
2008-01-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval Of Generic Prevacid® Delayed-Release Capsules tevapharm.com ↗

Evidence & citations 34 cited values

Every value below carries the sentence it was read from. 222 sources stand behind the page.

Field	Value	Cited text
Known as	lansoprazole	“Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40...” NCT00978016 ↗ 212 “sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe...” NCT01418300 ↗ “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on...” NCT04453189 ↗ “Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in...” NCT04325633 ↗ “A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn” NCT00389948 ↗ “Fifty patients receive lansoprazole 30 mg once plus mosapride 5 mg tid daily in the first month; and lansoprazole 30 mg once plus placebo tid daily in the second month.” NCT00729339 ↗ “Eligible patients were randomised to receive LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day) and lansoprazole (30 mg twice a day) for 7 days” PMID 20427390 ↗ May 2010 “Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days” NCT05371249 ↗ “triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)” NCT03654781 ↗ “Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days” NCT02112214 ↗ “lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days” NCT01537055 ↗ “Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.” NCT02788591 ↗ “Group 1 will receive clarithromycin 500 mg twice daily (bid), amoxicillin 1 g bid, and lansoprazole 30 mg bid (Pylopac®, Medix SA de CV, Mexico);” NCT02726269 ↗ “Patients were assigned randomly to groups given lansoprazole (30 mg twice daily) and bismuth potassium citrate (220 mg twice daily)” PMID 23376004 ↗ Jan 2013 “D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi” NCT01042184 ↗ “10-day HD-PPI-TT (60 mg lansoprazole/500 mg clarithromycin/1 g amoxicillin, each administered twice daily for 10 days)” PMID 29804294 ↗ Jun 2018 “Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days” NCT02557932 ↗ “Patients with inoperable gastric cancer were randomly assigned to receive oral lansoprazole (30 mg) or placebo daily.” PMID 28680717 ↗ May 2017 “Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects” NCT00230516 ↗ “Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days.” NCT01568944 ↗ “Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days” NCT05184491 ↗ “treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux” NCT00864396 ↗ “group two received lansoprazole (LAN) 60 mg p.o. bid for only one week before starting each of cycle” PMID 33394214 ↗ Jan 2021 “Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.” NCT01678027 ↗ “PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg)” NCT01643785 ↗ “Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.” NCT01005719 ↗ “Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast” NCT00903448 ↗ “Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.” NCT04660123 ↗ “PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer” NCT02288078 ↗ “omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole” NCT03094416 ↗ “gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole” NCT05761015 ↗ “lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)” NCT04713670 ↗ “Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole” NCT07611162 ↗ “Daily use of pantoprazole magnesium, rabeprazole or lansoprazole” NCT07076914 ↗ “lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm” NCT01906879 ↗ “one proton pump inhibitor: lansoprazole 30mg bid for 10d” NCT03571230 ↗ “Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g” NCT03317223 ↗ “lansoprazole/omeprazole combination” NCT01129713 ↗ “Lansoprazole 30mg once per day” NCT05899842 ↗ “Group L (lansoprazole 15 mg)” NCT02703896 ↗ “Lansoprazole: Prevacid” NCT01061437 ↗ “Taquidine,Lansoprazole” NCT00789061 ↗ “Drug: Lansoprazole” NCT05624229 ↗ “lansoprazole” NCT01005719 ↗ NCT05267743 ↗ NCT05050188 ↗ NCT07344506 ↗ NCT04729101 ↗ NCT00472186 ↗ NCT03498456 ↗ NCT06964334 ↗ NCT03120273 ↗ NCT06284876 ↗ NCT07708545 ↗ NCT00663897 ↗ NCT01008696 ↗ NCT03859102 ↗ NCT04400136 ↗ NCT01667718 ↗ NCT02633930 ↗ NCT00369265 ↗ NCT00442013 ↗ NCT00215787 ↗ NCT02278081 ↗ NCT00471094 ↗ NCT02251184 ↗ NCT03015610 ↗ NCT01123031 ↗ NCT00299845 ↗ NCT03355170 ↗ NCT03487562 ↗ NCT01082029 ↗ NCT04531475 ↗ NCT05417997 ↗ NCT00952913 ↗ NCT01481844 ↗ NCT07533266 ↗ NCT02873702 ↗ NCT04188119 ↗ NCT01182597 ↗ NCT00237068 ↗ NCT00175045 ↗ NCT03124420 ↗ NCT00467571 ↗ NCT05946135 ↗ NCT04022096 ↗ NCT02625259 ↗ NCT01180179 ↗ NCT00926809 ↗ NCT02755753 ↗ NCT00175032 ↗ NCT00251693 ↗ NCT00324974 ↗ NCT03059303 ↗ NCT01404832 ↗ NCT05259007 ↗ NCT00251719 ↗ NCT04248335 ↗ NCT00174928 ↗ NCT00204373 ↗ NCT03273634 ↗ NCT01175200 ↗ NCT03050359 ↗ NCT03794596 ↗ NCT07337655 ↗ NCT01279252 ↗ NCT00573924 ↗ NCT01046253 ↗ NCT02759393 ↗ NCT01046084 ↗ NCT00762359 ↗ NCT00708149 ↗ NCT02128490 ↗ NCT06894992 ↗ NCT04167670 ↗ NCT00825630 ↗ NCT06025773 ↗ NCT00644735 ↗ NCT01681186 ↗ NCT04840550 ↗ NCT00685295 ↗ NCT06931223 ↗ NCT05448001 ↗ NCT01045967 ↗ NCT00637416 ↗ NCT01131026 ↗ NCT00641602 ↗ NCT00361972 ↗ NCT02334501 ↗ NCT00701259 ↗ NCT04965298 ↗ NCT01512953 ↗ NCT06156085 ↗ NCT00352261 ↗ NCT05820048 ↗ NCT05055128 ↗ NCT02958046 ↗ NCT00854776 ↗ NCT03192059 ↗ NCT03050307 ↗ NCT02388581 ↗ NCT02388724 ↗ NCT03468777 ↗ NCT02388737 ↗ NCT07079540 ↗ NCT02761512 ↗ NCT01762657 ↗ NCT00458614 ↗ NCT01135368 ↗ NCT00211614 ↗ NCT04674774 ↗ NCT02892409 ↗ NCT02679508 ↗ NCT01459367 ↗ NCT00390390 ↗ NCT01820104 ↗ NCT01778101 ↗ NCT02022280 ↗ NCT00983034 ↗ NCT00149084 ↗ NCT00546117 ↗ NCT00410592 ↗ NCT00637845 ↗ NCT02139046 ↗ NCT01155284 ↗ NCT07479056 ↗ NCT03710434 ↗ NCT07037875 ↗ NCT02530879 ↗ NCT01456260 ↗ NCT01456247 ↗ NCT00837759 ↗ NCT03488173 ↗ NCT01946971 ↗ NCT01509261 ↗ NCT01506986 ↗ NCT04124926 ↗ NCT04341428 ↗ NCT01452698 ↗ NCT05933031 ↗ NCT00220818 ↗ NCT03130452 ↗ NCT05711810 ↗ NCT01452763 ↗ NCT01452750 ↗ NCT04660461 ↗ NCT05010954 ↗ NCT01452724 ↗ NCT01505127 ↗ NCT00942175 ↗ NCT01452711 ↗ NCT01147588 ↗ NCT04101708 ↗ NCT00220909 ↗ NCT00335283 ↗ NCT04874935 ↗ NCT00625274 ↗ NCT03524833 ↗ NCT02175901 ↗ NCT07313774 ↗ NCT02175927 ↗ NCT01040455 ↗ NCT01039558 ↗ NCT03488186 ↗ NCT03418337 ↗ NCT01607918 ↗ NCT05861687 ↗ NCT05926804 ↗ NCT01037452 ↗ NCT01216267 ↗ NCT06945237 ↗ NCT00787254 ↗
Known as	A-65006	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	AD-2121	“AD-2121 (Lansoprazole 15 mg), Oral, Capsule” NCT06025773 ↗
Known as	AG-1749	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Agopton	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	LAN	“group two received lansoprazole (LAN) 60 mg p.o. bid for only one week before starting each of cycle” PMID 33394214 ↗ Jan 2021
Known as	Lansoprazol	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Lansoprazole (generic name)	“Lansoprazole (generic name)” NCT01045967 ↗ 2 “Lansoprazole (generic name)” NCT01046084 ↗ “Lansoprazole (generic name)” NCT01046253 ↗
Known as	Lansoprazole component of prevpac	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Lansoprazole is marketed as Prevacid.	“Lansoprazole is marketed as Prevacid.” NCT00204373 ↗
Known as	lansoprazole or Prevacid	“lansoprazole or Prevacid” NCT00467571 ↗
Known as	Lansoprazole Teva	“Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin” NCT03192059 ↗
Known as	Lansoprazole: Prevacid	“Lansoprazole: Prevacid” NCT01061437 ↗
Known as	Lansox	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Lanzoprazole	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01139645 ↗
Known as	Lanzor	“1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily” NCT01139645 ↗
Known as	Limpidex	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	NSC-758638	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Ogast	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Ogastoro	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Opiren	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	prevacid	“The proposed study is a randomized controlled trial in which children with nasal obstruction will be randomized to receive either antireflux medication lansoprazole (prevacid)...” NCT02278081 ↗ 12 “iv esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®” NCT00230516 ↗ “Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.” NCT01005719 ↗ “Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast” NCT00903448 ↗ “proton pump inhibitors (ppi; Prevacid, Nexium).” NCT02794844 ↗ “Lansoprazole (Prevacid)” NCT00211614 ↗ “Lansoprazole (Prevacid)” NCT00546117 ↗ NCT00239551 ↗ NCT00444145 ↗ NCT02387203 ↗ NCT00274339 ↗ NCT00638456 ↗ NCT00864396 ↗
Known as	Prevacid 24 hr	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Prevacid delayed release	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Prevacid is the brand name for this drug	“Prevacid is the brand name for this drug” NCT00215787 ↗
Known as	Prevacid iv	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Prevacid solutab	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Prevonco	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Known as	Takepron	“lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)” NCT04713670 ↗ 2 “lansoprazole (Takepron) 30mg po qid” NCT04101708 ↗ NCT06778824 ↗
Known as	Takepron OD	“oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks” NCT03418337 ↗ 1 “Lansoprazole (Takepron OD) 30mg q12h PO” NCT01182597 ↗
Known as	Zoton	ChEMBL registry synonym — accepted as the source's own label CHEMBL480 ↗
Action	Inhibit	“Lansoprazole ( i.e., proton pump inhibitor)” NCT00237068 ↗
Modality	Other / unclassified	“a proton pump inhibitor” PMID 19183157 ↗ Apr 2009
Route	Oral	“Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.” NCT00174928 ↗